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Editor’s note
The International Masters Frontier Forum at Sun Yat-
sen University was held in the Seventh Affiliated Hospital 
of Sun Yat-sen University on May 12, 2018. During the 
forum, Professor Brandner has given a lecture on the topic 
“Molecular diagnostics of brain tumours: the next frontiers”. 
Annals of Translational Medicine (ATM) was honored to 
conduct an interview to conduct an interview with Professor 
Brandner to share his research focus, research experience 
and perspective, providing updated knowledge of research 
on brain tumours among his team and some suggestions 
for colleagues to translate the advanced knowledge in 
laboratory into the daily practice and clinical fields.
Expert’s introduction
Sebas t ian  Brandner  (Figure  1 )  i s  a  Professor  o f 
Neuropathology at University College London (UCL) and 
Head of the Division of Neuropathology at the National 
Hospital, University College London Hospitals NHS 
Foundation Trust. He studied medicine in Göttingen, 
Germany where he obtained his MD degree in experimental 
neurobiology, at the Max Planck Institute for Biophysical 
Chemistry. He trained in diagnostic neuropathology in 
Zürich, Switzerland. In 2001, he was recruited through the 
Medical Research Council international recruitment scheme 
and in 2004 he was appointed Professor of Neuropathology. 
Professor Brandner and his research team established 
mouse models for brain tumours. One of their key 
achievements is the demonstration of genotype-phenotype 
correlation brain tumours and identifying the cell of 
origin of gliomas in mice. Molecular profiling of mouse 
tumours could demonstrate a strong correlation to certain 
types of human gliomas, thus making it a valuable model 
for technology development, and biomarker discovery. 
His group has recently discovered biomarkers (miR-449a 
and GPR158) that correlate with survival of patients with 
gliomas, making it a potential druggable target. Results 
of his research are published in EMBO Journal, Cancer 
Research, Disease Models and Mechanisms, and Oncogene. 
Collaborative work published in Cancer Cell oor PNAS. 
In the field of neurodegeneration, Professor Brandner led 
two national vCJD surveillance studies, published in BMJ 
and a study on the human transmission of amyloid beta 
through medical procedures, published in Nature and Acta 
Neuropathologica.
Interview
ATM: Your speech topic is Molecular diagnostics of brain 
tumours: the next frontiers. Would you please introduce 
what are the main methods of the molecular diagnostics 
and why they could be the next frontiers? 
Professor Brandner: Following an initial histological 
assessment, we are using mutation specific antibodies 
to discriminate the most common tumour classes. The 
next step is the further characterisation with single target 
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sequencing and copy number assays. The reason for 
recommending this relatively simple technology is the wide 
availability, speed and cost effectiveness of this approach. If 
used in a DNA-based approach (as opposed to fluorescence 
in situ hybridisation, a tissue-based approach) it can be 
very cost-effective and scalable, and it can be implemented 
in most molecular biology laboratories associated with 
pathology departments. The next frontiers that I was 
referring to are the use of test methods to interrogate 
epigenetic profiles of brain tumours. This technology is 
based on the uniqueness of epigenetic modifications that 
correlate with classes of tumours. The technology that 
allows the rollout in clinical practice is array-based and 
the use of “machine learning” has led to the development 
of algorithms that can discriminate distinct "methylation 
classes" of brain tumours. This technology was developed 
at the German Cancer research Centre in Heidelberg and 
is now available to clinicians and researchers worldwide. 
In many instances, methylation classes overlap with 
histological and molecular entities (such as histone mutant 
gliomas or IDH mutant gliomas), but there is a proportion 
of tumours where the histology can vary widely, yet these 
tumours belong to a single methylation class. Conversely, 
the methylation profiling can also identify distinct 
methylation classes within a cohort of tumours that look 
indistinguishable or very similar for the microscope. The 
next frontiers are therefore the logical and evidence-based 
implementation of such technologies into clinical practice.
ATM: You have focused on research of experimental models 
and their translation to human diseases. What is the up-
to-date progress ? How could they help with the clinical 
treatments in the future?
Professor Brandner: Progress on experimental models 
and their translation to human diseases is manifold and not 
restricted to a specific type of model. It is always essential 
to understand that a good model does not necessarily aim 
at recapitulating all aspects of human diseases. In fact, the 
best models may be those which reliably, faithfully, and 
reproducibly represent a few key features of human disease. 
Establishing precise models is challenged by the gap of 
knowledge of the cell of origin, window of opportunity, 
and matching mutations. Models to assess treatment 
options may work very differently and may include cellular 
transplant strategies, genetic editing of human cells and in 
vitro models as a first-line assessment of drug targets.
ATM: What do you think are the biggest challenges in 
brain tumours researches currently?
Professor Brandner: One of the biggest challenges is the 
identification of druggable targets and subsequently the 
cost-effective development of drugs that can effectively 
interact with these targets. Repurposing of drugs has 
recently been a significant topic of debate, providing 
potential access to a wide range of tested and proven drugs, 
and making them available for specifically identified targets. 
ATM: How to better translate the advanced knowledge 
and technologies in laboratory into the daily practice of 
pathological diagnosis and clinical fields?
Professor Brandner: There are several factors that need 
to be considered in introducing advanced knowledge 
and technologies in laboratories for daily practice. 
First, a thorough training of pathologists to understand 
molecular pathways, and their integration into their 
histology diagnostics. In many fields of pathology, 
including neuropathology, we are moving away from the 
histological classification alone, and increasingly integrate 
the morphological approach with a  biomarker-driven 
diagnostic approach. This approach of course always starts 
with the recognition of a basic pathology in general (for 
example inflammation, degeneration, neoplasia) and then 
(in the context of neuro-oncology) with an assessment of 
the tumour type (for example, glioma, meningioma, germ-
cell tumour, or primitive neuroectodermal tumour, to 
name a few). The next essential step is the correct choice 
of molecular markers to be tested. This is of course again 
in a certain way hypothesis driven, as pathologist needs to 
understand which of the biomarkers to test for. There are 
two outcomes: (I) one of the biomarkers is positive and 
the tumour is molecularly defined. A smaller proportion 
of tumours may not have informative biomarkers, and (II) 
these require further testing with advanced technologies, 
for example methylation arrays for the improved, evidence-
based classification according to established methylation 
classes.
For a cost-effective implementation into clinical practice 
it is essential to build centres that have sufficiently large 
catchment areas to serve a substantial population base. This 
allows for the cost-effective economy of scale, enabling 
pathologists to see reasonable numbers even of rare tumour 
types, and laboratory to implement tests even for rare 
mutations in cost-effective fashion. Finally, it is essential 
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to build up a larger team of specialised pathologists, who 
can exchange and build up knowledge even in a highly 
specialised area within pathology (and correspondingly in 
any other area of medicine).
ATM: It is said that we are now in the era of precision 
medicine. What do you think would be the focus or future 
trend of precision medicine researches on neuropathology 
in the next 5–10 years? 
Professor Brandner: In my opinion we are just entering 
the era of precision medicine. I think as yet we are far 
away from the rollout of precision medicine. As for now, 
neuropathology has just identified diagnostic biomarkers 
(most developments happened the last 10 years) and it will 
take another 10 or 15 years for the oncology community to 
develop drugs that can target these pathways. The advance 
of epigenetic profiling (see above) will have to be combined 
with confirmatory testing for druggable targets (single 
mutations or pathways) and this will form the basis for 
precision medicine.
ATM: In retrospect, what do you think motivated/inspired 
you to study brain tumours?
Professor Brandner: During medical school I worked 
on the identification of anatomical pathways in the brain, 
specifically looking at the projection of neurons from the 
auditory cortex to the thalamus. This was fascinating, 
but did not help me understanding diseases. After 
medical school, as a junior doctor I was on a placement 
in neurosurgery. During the clinical team meetings, I 
was fascinated, but also confused by the neuropathology 
terminology, and how pathologists arrived at a diagnosis. 
These were the times when antibodies against lineage 
markers such as cytokeratin,  GFAP, S 100 or the 
proliferation marker Ki67 had just been developed and were 
rolled out into neuropathology diagnostics. At the time, this 
was revolutionary, as it helped for example discriminating 
epithelial from glial tumours. To better understand how 
brain tumours are diagnosed and classified and ideally also 
to understand their biology, I joined the Department of 
Neuropathology at the University of Zürich, where I met 
my early mentor Professor Kleihues who was at the time 
the editor of the WHO classification. I was part of an active 
team , at an Institute that led the field in brain tumour 
diagnosis and research. Over the next few years, whilst 
completing my training in neuropathology I developed 
two interests experimental pathology, neurodegeneration 
and neuro-oncology. I started building up my own team 
in brain tumour research and I was fascinated by the 
opportunities that the mouse models (at the time transgenic 
mice and conditional knockout mice; the Cre lox system 
had just been developed) provided us to study the function 
of genes and their role in causing stem cells to become 
tumour precursors. Since then I have always enjoyed 
the combination of diagnostic work, which gave me the 
opportunity to apply my molecular pathology knowledge to 
establishing a large molecular test service, and at the same 
time comparing the human biology with mouse models that 
are generated myself. 
ATM: What do you think are the most important qualities 
to be a researcher or scientist?
Professor Brandner: In my view scientific success depends 
on 3 factors (of course highly simplified): Working at 
the right time in the right environment, hard work and 
incredible amount of luck.
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